Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 04, 2024 07:46 ET | Source: ANEW MEDICAL, INC.

Healthy Longevity is One of Key Development Goals of ANEW’s Novel Gene Therapy

Healthy Longevity is One of Key Development Goals of ANEW’s Novel Gene Therapy
September 04, 2024 03:00 ET | Source: Harness Therapeutics

Harness Therapeutics Appoints Experienced R&D Executive and Physician-Scientist, Dr Paulo Fontoura, as Non-Executive Director

Dr Paulo Fontoura brings 20 years’ experience of working in the pharma industry, with the most recent 16 years focusing on translational medicine and clinical development approaches for one of the...
August 28, 2024 09:00 ET | Source: AC Immune SA

AC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions

AC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions PI-2620 is in Phase 3 development in Alzheimer’s disease by AC Immune’s...
August 19, 2024 05:00 ET | Source: ANEW MEDICAL, INC.

ANEW MEDICAL, INC. Appoints New CFO

ANEW MEDICAL, INC. Appoints New CFO
August 15, 2024 05:00 ET | Source: ANEW MEDICAL, INC.

ANEW MEDICAL, INC. Strengthens Intellectual Property Protection with U.S. Patent Issuance for Its Secreted RNA Splice Variant of the Human Klotho Gene Used for the Treatment of Neurodegenerative and Age-Related Diseases

NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. (“ANEW” or “the Company”) (NASDAQ: WENA) a U.S. -based biotechnology company focused on developing cell and gene-based treatments for...
July 31, 2024 08:30 ET | Source: AC Immune SA

AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024

AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024 morADC combines proprietary brain-penetrant small...
June 26, 2024 08:00 ET | Source: Annovis Bio, Inc.

Annovis Bio Files Patent for New Composition of Matter for Buntanetap

MALVERN, Pa., June 26, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies...
June 25, 2024 08:00 ET | Source: Annovis Bio, Inc.

Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast to Discuss Parkinson’s Disease Data

MALVERN, Pa., June 25, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies...
June 18, 2024 08:00 ET | Source: Annovis Bio, Inc.

Annovis Bio Highlights New Alzheimer’s Data at the Alzheimer’s Association International Conference® 2024

MALVERN, Pa., June 18, 2024 (GLOBE NEWSWIRE) -- via IBN -- Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage drug platform company developing novel therapies for...
May 28, 2024 11:21 ET | Source: Dimension Market Research

Amyotrophic Lateral Sclerosis Market On Track For USD 1,271.6 Mn Revenue By 2033, Growing At 6.5% CAGR | Dimension Market Research

New York, May 28, 2024 (GLOBE NEWSWIRE) -- Market Overview The Global Amyotrophic Lateral Sclerosis Market size was valued at USD 673.4 million in 2023 and is further anticipated to reach USD...